Application of forsythin in preparation of medicine for preventing or treating muscular atrophy

By using forsythoside to inhibit 15-PGDH and increase endogenous PGE2 levels, the side effect risks of existing drug treatments for muscle atrophy are eliminated, providing a safe and effective treatment option for muscle atrophy that significantly improves muscle quality and function.

CN121401285APending Publication Date: 2026-01-27KAIDU (CHENGDU) BIOTECHNOLOGY CO LTD
3 Cites 0 Cited by

Patent Information

Application Number
CN202512004145.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-29
Publication Date
2026-01-27

AI Technical Summary

Technical Problem

Currently, there is a lack of highly effective and safe 15-PGDH inhibitors, especially those derived from natural products, for the development of drugs to treat muscle atrophy. Existing drug treatments carry the risk of side effects, and non-drug treatments are difficult to maintain their effectiveness.

Method used

Forsythoside is proposed for use in the preparation of drugs for the prevention or treatment of muscle atrophy. It promotes muscle regeneration by inhibiting the activity of 15-PGDH, increasing the level of endogenous prostaglandin E2, regulating the PGE2 pathway, activating muscle satellite cells.

Benefits of technology

Forsythoside significantly improves dexamethasone-induced muscle atrophy in mice, increases muscle weight and muscle fiber area, restores muscle function, reduces the proportion of slow-twitch muscle fibers, and decreases the expression of FOXO3a and Atrogin-1, providing a safe and effective treatment for muscle atrophy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the field of biological medicines, and particularly relates to a novel application of forsythin in preparation of a medicine for preventing and treating amyotrophy. In-vivo and in-vitro experiments prove that the phillyrin can remarkably improve the level of endogenous prostaglandin E2 by inhibiting the activity or expression of 15-hydroxyprostaglandin dehydrogenase in muscular tissues, so that the expression of muscular atrophy key factors FOXO3a and Atrogin-1 is inhibited, and finally the effects of protecting muscle quality and improving muscle functions are achieved. The invention reveals that forsythin has the functions of inhibiting 15-PGDH and relieving muscle atrophy for the first time, and brand new medical application is provided for forsythin. The invention provides a brand-new therapeutic scheme and pharmaceutical composition for treating sarcopenia by using forsythin as an active component and regulating the 15-PGDH / PGE2 pathway. The invention provides an important candidate compound for developing efficient and safe sarcopenia resisting medicines, and has important practical significance.
Need to check novelty before this filing date? Find Prior Art